The study is published online Nov. 11 in the journal Breast Cancer Research and Treatment. Preliminary findings were presented in 2010 at the 74th Annual Scientific Meeting of the American College of Rheumatology.
For many post-menopausal women with breast cancer promoted by the hormone estrogen, aromatase inhibitors (AI) can dramatically reduce the risk of their cancer coming back. Doctors say the AIs must be taken for five years to gain the full benefit, however, the development of joint complaints in up to 35 percent of women forces many of them to stop early out of concern that the pain signals a more serious condition.
"It's not clear why joint symptoms occur with AI use, but we wondered if it could be related to inflammation or an autoimmune disease," says rheumatologist Victoria K Shanmugam, MBBS, MRCP, assistant professor of medicine at Georgetown University Medical Center, and the study's lead author. "Our research ruled out both."
Forty-eight postmenopausal women with state I, II or III breast cancer treated at Georgetown Lombardi Comprehensive Cancer Center were invited to take part in the study. All had hand pain and no known autoimmune disease. Of them, 25 women were taking AIs; 23 women were not taking AIs.
Subjects were evaluated after abstaining from non-steroidal anti-inflammatory drugs for 48 hours. Signs of inflammation from arthritis would reappear in that time frame, the researchers reasoned. All the women completed a health assessment questionnaire. The rheumatologist conducted a personal history and physical examination with each patient. Various blood tests were conducted and x-rays and ultrasounds of all participants' hands were performed. The rheumatologist and radiologist did not know which participants were taking AIs and which were not.
"We found that several patients in the control arm had a similar constellation of symptoms to those receiving AIs, but our team did not find any conclusive evidence that women taking AIs were more likely to have inflammatory arthritis or an autoimmune disease," Shanmugam says.
An autoimmune disease was discovered in four of the 48 women – two in each group -- that had previously been undiagnosed. The cases were equally distributed among cases and controls.
"It would be prudent to refer those experiencing joint pain to a rheumatologist to rule out a previously undiagnosed autoimmune disease, and so that we can help address the symptoms," Shanmugam says.
"Although our study helps to rule out inflammatory arthritis or autoimmune disease as cause for joint pain associated with AIs, we still do not know why these women have musculoskeletal symptoms. Since the syndrome doesn't appear to be related to inflammatory arthritis or autoimmune disease, women should be encouraged to stay on their medication so they can gain the full benefit from it."
The authors report no related financial interests. This work was supported by a development grant from the Georgetown University Hospital Department of Internal Medicine, and by the Swing Fore the Cure Foundation. Shanmugam was supported by the Physician Scientist Development Award from the American College of Rheumatology Research and Education Foundation and is currently supported awards from the National Center for Research Resources at National Institutes of Health. In addition, Shanmugam is supported by a KL2 Mentored Career Development Program Scholar grant from Georgetown-Howard Universities Center for Clinical & Translational Science.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2010-11, GUMC accounted for 85 percent of the university's sponsored research funding.
Karen Mallet | EurekAlert!
Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University
Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
16.11.2018 | Health and Medicine
16.11.2018 | Life Sciences
16.11.2018 | Life Sciences